生物学的同等性 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "生物学的同等性" in Japanese language version.

refsWebsite

Global rank Japanese rank

447^th place

1,043^rd place

4^th place

24^th place

2^nd place

6^th place

2web.archive.org

1^st place

1^st place

68^th place

425^th place

1australianprescriber.com

low place

low place

195^th place

376^th place

2,814^th place

4,178^th place

1peoplespharmacy.com

low place

low place

137^th place

1,092^nd place

australianprescriber.com

Birkett DJ (2003). “Generics - equal or not?”. Aust Prescr 26 (4): 85–7. doi:10.18773/austprescr.2003.063 4 November 2013閲覧。. Birkett DJ (2003). "Generics - equal or not?" (PDF). Aust Prescr. 26 (4): 85–7. doi:10.18773/austprescr.2003.063. Archived from the original (PDF) on 15 April 2013. Retrieved 4 November 2013.

cell.com

http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(15)00241-2

doi.org

Birkett DJ (2003). “Generics - equal or not?”. Aust Prescr 26 (4): 85–7. doi:10.18773/austprescr.2003.063 4 November 2013閲覧。. Birkett DJ (2003). "Generics - equal or not?" (PDF). Aust Prescr. 26 (4): 85–7. doi:10.18773/austprescr.2003.063. Archived from the original (PDF) on 15 April 2013. Retrieved 4 November 2013.
Midha KK, McKay G (2009). “Bioequivalence; its history, practice, and future”. AAPS J 11 (4): 664–70. doi:10.1208/s12248-009-9142-z. PMC 2782076. PMID 19806461.

europa.eu

ema.europa.eu

Committee for Medicinal Products for Human Use (20 January 2010). “Guideline on the Investigation of Bioequivalence”. European Medicines Agency. 21 April 2011閲覧。
“EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs”. European Medicines Agency (2017年3月24日). 2020年11月17日閲覧。

fda.gov

Center for Drug Evaluation and Research (2003年). “Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations”. United States Food and Drug Administration. 2021年3月17日閲覧。Center for Drug Evaluation and Research (2003). "Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations" (PDF). United States Food and Drug Administration.
“Review of therapeutic equivalence: generic bupropion XL 300 mg and Wellbutrin XL 300 mg”. 6 June 2011時点のオリジナルよりアーカイブ。19 April 2008閲覧。
"Budeprion XL 300 mg not therapeutically equivalent to Wellbutrin XL 300 mg" (Press release). FDA. 3 October 2012. 2013年3月23日閲覧。
“FDA Update”. FDA (October 2013). 15 June 2015閲覧。

nbcnews.com

Stenson, Jacqueline (12 October 2007). “Report questions generic antidepressant”. NBC News. 13 October 2007閲覧。

nih.gov

ncbi.nlm.nih.gov

Midha KK, McKay G (2009). “Bioequivalence; its history, practice, and future”. AAPS J 11 (4): 664–70. doi:10.1208/s12248-009-9142-z. PMC 2782076. PMID 19806461.

pmc.ncbi.nlm.nih.gov

Midha KK, McKay G (2009). “Bioequivalence; its history, practice, and future”. AAPS J 11 (4): 664–70. doi:10.1208/s12248-009-9142-z. PMC 2782076. PMID 19806461.

pubmed.ncbi.nlm.nih.gov

Midha KK, McKay G (2009). “Bioequivalence; its history, practice, and future”. AAPS J 11 (4): 664–70. doi:10.1208/s12248-009-9142-z. PMC 2782076. PMID 19806461.

peoplespharmacy.com

“Generic drug equality questioned”. 13 October 2007閲覧。

web.archive.org

Birkett DJ (2003). “Generics - equal or not?”. Aust Prescr 26 (4): 85–7. doi:10.18773/austprescr.2003.063 4 November 2013閲覧。. Birkett DJ (2003). "Generics - equal or not?" (PDF). Aust Prescr. 26 (4): 85–7. doi:10.18773/austprescr.2003.063. Archived from the original (PDF) on 15 April 2013. Retrieved 4 November 2013.
“Review of therapeutic equivalence: generic bupropion XL 300 mg and Wellbutrin XL 300 mg”. 6 June 2011時点のオリジナルよりアーカイブ。19 April 2008閲覧。

who.int

WHO guidelines on Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability WHO Technical Report Series, No. 1003, 2017, Annex 6